摘要
背景:2019年冠状病毒病(COVID-19)成为近代人类历史上的主要健康问题,全球有成千上万的死亡和数百万例病例。对其他冠状病毒的最新研究和较旧的经验强调了可能与SARS-CoV-2感染的内在作用有关的肾素-血管紧张素系统(RAS)紊乱的潜在机制。 目的:在这篇综述中,我们旨在描述RAS成分,免疫系统和COVID-19病理生理学之间的紧密联系。 方法:这篇非系统性的综述文章总结了有关COVID-19与RAS之间关系的最新证据。 结果:多项研究表明,膜结合ACE2的下调可能对免疫功能受损和COVID-19患者的预后起着关键作用。下调可能通过不同的机制发生,特别是:(1)SARS-CoV-2融合途径诱导的脱落过程,这减少了膜结合的ACE2的数量,高水平的血管紧张素II刺激了更多的脱落; (2)ACE2受体与病毒本身的内吞作用;(3)SARS-CoV-2引起的干扰素抑制作用对免疫系统的影响,导致ACE2受体表达降低。 结论:最近的研究提供了减少替代RAS轴的成分的证据,包括ACE2和血管紧张素-(1-7)。相反,增加的血管紧张素II水平可以激活几个器官中的AT1受体。因此,感染SARS-COV-2的患者发炎,血栓形成和血管生成增加。应主要在新型疫苗和拟用药物的背景下,注意RAS与COVID-19的相互作用。
关键词: COVID-19,SARS-COV-2,RAS,下调,ACE2受体,血管紧张素II,血管紧张素(1-7)。
图形摘要
Current Drug Targets
Title:Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Volume: 22 Issue: 3
关键词: COVID-19,SARS-COV-2,RAS,下调,ACE2受体,血管紧张素II,血管紧张素(1-7)。
摘要:
Background: The Coronavirus Disease 2019 (COVID-19) is becoming the major health issue in recent human history with thousands of deaths and millions of cases worldwide. Newer research and old experience with other coronaviruses highlighted a probable underlying mechanism of disturbance of the renin-angiotensin system (RAS) that is associated with the intrinsic effects of SARS-CoV-2 infection.
Objective: In this review, we aimed to describe the intimate connections between the RAS components, the immune system and COVID-19 pathophysiology.
Methods: This non-systematic review article summarizes recent evidence on the relationship between COVID-19 and the RAS.
Results: Several studies have indicated that the downregulation of membrane-bound ACE2 may exert a key role for the impairment of immune functions and for COVID-19 patients’ outcomes. The downregulation may occur by distinct mechanisms, particularly: (1) the shedding process induced by the SARS-CoV-2 fusion pathway, which reduces the amount of membrane-bound ACE2, stimulating more shedding by the high levels of Angiotensin II; (2) the endocytosis of ACE2 receptor with the virus itself and (3) by the interferon inhibition caused by SARS-CoV-2 effects on the immune system, which leads to a reduction of ACE2 receptor expression.
Conclusion: Recent research provides evidence of a reduction of the components of the alternative RAS axis, including ACE2 and Angiotensin-(1-7). In contrast, increased levels of Angiotensin II can activate the AT1 receptor in several organs. Consequently, increased inflammation, thrombosis and angiogenesis occur in patients infected with SARS-COV-2. Attention should be paid to the interactions of the RAS and COVID-19, mainly in the context of novel vaccines and proposed medications.
Export Options
About this article
Cite this article as:
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology, Current Drug Targets 2021; 22 (3) . https://dx.doi.org/10.2174/1389450121666201020154033
DOI https://dx.doi.org/10.2174/1389450121666201020154033 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Current Neurovascular Research Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
Current Medicinal Chemistry Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases
Current Vascular Pharmacology Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry The Dynamic Progress of Myocardial Infarction Studied by Spectroscopic Techniques
Current Metabolomics Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?
Current Vascular Pharmacology Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design